Human ACE-2 Antibody

Catalog #: MAB10826 Datasheet / COA / SDS

Catalog #	Availability	Size / Price	Qty
MAB10826-100
MAB10826-SP

Detection of Human ACE‑2 by Western Blot.

2 Images

All ACE-2 Antibodies

Product Details

Supplemental Products

Reviews

Summary Data Examples Preparation and Storage Reconstitution Calculator Background Product Datasheets Related Research Areas

Human ACE-2 Antibody Summary

Species Reactivity

Human

Specificity

Detects human ACE-2 in direct ELISAs.

Source

Monoclonal Mouse IgG_2A Clone # 1038225

Purification

Protein A or G purified from hybridoma culture supernatant

Immunogen

Mouse myeloma cell line NS0-derived human ACE-2
Gln18-Ser740
Accession # Q8BYF1

Formulation

Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.

Label

Unconjugated

Applications

Recommended Concentration

Sample

Western Blot

2 µg/mL

Human testis

Immunohistochemistry

5-25 µg/mL

Immersion fixed paraffin-embedded sections of human kidney

Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.

Scientific Data

Western Blot

View Larger

Detection of Human ACE‑2 by Western Blot. Western blot shows lysates of human testis. PVDF membrane was probed with 2 µg/mL of Mouse Anti-Human ACE‑2 Monoclonal Antibody (Catalog # MAB10826) followed by HRP-conjugated Anti-Mouse IgG Secondary Antibody (HAF018). A specific band was detected for ACE‑2 at approximately 120 kDa (as indicated). This experiment was conducted under reducing conditions and using Western Blot Buffer Group 1.

Immunohistochemistry

View Larger

ACE‑2 in Human Kidney. ACE‑2 was detected in immersion fixed paraffin-embedded sections of human kidney using Mouse Anti-Human ACE‑2 Monoclonal Antibody (Catalog # MAB10826) at 5 µg/mL for 1 hour at room temperature followed by incubation with the Anti-Mouse IgG VisUCyte™ HRP Polymer Antibody (VC001). Before incubation with the primary antibody, tissue was subjected to heat-induced epitope retrieval using Antigen Retrieval Reagent-Basic (CTS013). Tissue was stained using DAB (brown) and counterstained with hematoxylin (blue). Specific staining was localized to cell membranes in convoluted tubules. Staining was performed using our protocol for IHC Staining with VisUCyte HRP Polymer Detection Reagents.

Reconstitution Calculator

Preparation and Storage

Reconstitution

Reconstitute at 0.5 mg/mL in sterile PBS.

Shipping

Lyophilized product is shipped at ambient temperature. Liquid small pack size (-SP) is shipped with polar packs. Upon receipt, store immediately at the temperature recommended below.

Stability & Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles.

12 months from date of receipt, -20 to -70 °C as supplied.
1 month, 2 to 8 °C under sterile conditions after reconstitution.
6 months, -20 to -70 °C under sterile conditions after reconstitution.

Background: ACE-2

Angiotensin I Converting Enzyme (ACE-2), also called ACEH (ACE homologue), is a dimeric, zinc-dependent metalloprotease of the ACE family that also includes somatic and germinal ACE (1, 2). ACE-2 mRNA is found at high levels in heart, testis, and kidney and at lower levels in a wide variety of tissues (1, 3). ACE-2 is the SARS-CoV and SARS-CoV2 Spike protein receptor in vivo (4-6), functions catalytically as a carboxypeptidase to cleave several substrates including angiotensins I and II, and acts as a partner for B0AT1-family amino acid transporters (1, 2). Through these functions, ACE-2 has been shown to be involved in several diseases including SARS, COVID19, acute lung injury (4, 7), heart disease (8), liver and lung fibrosis (9), inflammatory lung disease (10), and cardiopulmonary disease (11). Full length ACE-2 protein includes an extracellular region composed of a single N-terminal peptidase domain and C-terminal collectrin-like domain (CLD), a transmembrane domain, and a short cytoplasmic tail (12). The N-terminal peptidase region is required for binding to SARS-CoV and SARSCoV2 spike proteins, while the CLD contains a region that promotes dimerization and association with amino acid transporters (2). The peptidase domain contains a long deep cleft that undergoes a large hinge-bending movement at substrate and inhibitor binding (12). Classical ACE inhibitors such as captopril and lisinopril do not inhibit ACE-2 activity and inhibitors of ACE-2 do not inhibit ACE activity (13).

References

Kuba, K. et al. (2010) Pharmacol. Ther. 128:119.
Yan, et al. (2020) Science 367:1444.
Tipnis, S.R. et al. (2000) J. Biol. Chem. 275:33238.
Kuba, K. et al. (2005) Nature Med. 11:875.
Hoffmann, M. et al. (2020) Cell.181:1.
Wrapp, et al. (2020) Science 367:1260.
Imai, Y. et al. (2005) Nature 436:112.
Huang, L. et al. (2003) J. Biol. Chem. 278:15532.
Schrom, E. et al. (2017) Mol. Therapy Nuc. Acid 7:350.
Jia, H. et al. (2016) Shock. 46:239.
Cole-Jeffrey, C.T. et al. (2015) J. Cadiovasc. Pharmacol. 66:540.
Towler, P. et al. (2004) J. Biol. Chem. 279:17996.
Crackower, M.A. et al. (2002) Nature 417:822.

Long Name

Angiotensin I Converting Enzyme 2

Entrez Gene IDs

59272 (Human); 70008 (Mouse); 302668 (Rat); 100144303 (Porcine); 480847 (Canine); 418623 (Chicken); 102130864 (Cynomolgus Monkey); 554349 (Feline); 101673097 (Ferret); 101823817 (Hamster); 108390919 (Malayan Pangolin)

Alternate Names

ACE2; ACE-2; ACEH; ACEHangiotensin I converting enzyme 2; ACE-related carboxypeptidase; angiotensin I converting enzyme (peptidyl-dipeptidase A) 2; angiotensin-converting enzyme 2; Angiotensin-converting enzyme homolog; DKFZp434A014; EC 3.4.17; EC 3.4.17.23; Metalloprotease MPROT15